Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease
Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson's disease (PD) cohort and explore the related plasma biomarkers. Background: Depression and anxietyare common non-motor…Role of ATP10B variants in Parkinson Disease in a southern Spanish cohort
Objective: The objective of our study was to evaluate the role of ATP10B variants in Parkinson disease (PD) in a southern Spanish cohort of PD…Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis
Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…Physical exercise as a promising option for treating fatigue in Parkinson’s disease? Results of a systematic review and meta-analysis of non-pharmacological interventions
Objective: To give an update on randomized controlled trials (RCT) including non-pharmacological intervention approaches that examine effects on fatigue in people with Parkinson’s disease (PD).…Using mediation analysis to account for the effect of Parkinson’s Disease medications on disease progression
Objective: To explore the use of mediation analysis to incorporate L-dopa equivalent daily dose (LEDD) for disease progression of Parkinson’s Disease (PD) in a simulation…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson’s disease
Objective: To investigate the effectiveness of a two-dimensional gait assessment to identify the decline in gait performance associated with Parkinson's disease progression Background: Gait is…Continuous estimation of Parkinson’s on-off states using wearable devices
Objective: Utilize passive, continuous data from mobile and wearable devices to estimate on-off states in Parkinson’s patients. Background: The Hauser motor diary is often used…
- « Previous Page
- 1
- …
- 342
- 343
- 344
- 345
- 346
- …
- 553
- Next Page »